贝伐珠单抗致术后切口愈合延迟1例

Analysis of One Case of Bevacizumab-induced Delayed Wound Healing

报道贝伐珠单抗所致的手术切口愈合延迟1例。贝伐珠单抗(Bevacizumab)作为血管内皮生长因子(vascular endothelial growth factor,VEGF)的人源化单克隆抗体,FDA已批准用于转移性结直肠癌等多种肿瘤的一线治疗。该病例发现其可能会导致术后切口愈合延迟及增加手术并发症(包括严重及致命的),故在临床应用该药过程中,医护人员应特别注意避免在贝伐珠单抗治疗期间行创伤性操作。如紧急情况,应仔细评估风险和权衡利弊,及时做好应对措施,保障患者用药安全。

We report a case of bevacizumab-relevant delayed wound healing.Bevacizumab,a humanized monoclonal antibody which specifically binds to vascular endothelial growth factor(VEGF),has been approved by FDA for first-line treatment of a variety of tumors.Due to its potential for delayed wound healing and increased incidence of surgical complications,clinician doctors should pay special attention to avoid surgical treatment and other traumatic operations during the treatment of bevacizumab.In case of emergency,the risks should be carefully assessed and the pros and cons should be weighed,and the corresponding measures should be taken in time to ensure the drug safety of patients.